Symbols / ALEC
ALEC Chart
About
Alector, Inc., a clinical stage biotechnology company, develops therapies to counteract the progression of neurodegeneration in the United States. Its pipeline includes Nivisnebart, an investigational human recombinant monoclonal antibody for treating prevalent neurodegenerative diseases; AL137, an anti-amyloid beta antibody paired in preclinical development for the potential treatment of Alzheimer's disease; and AL050, a GCase enzyme replacement therapy in preclinical development for the potential treatment of Parkinson's disease and Lewy body dementia in patients having GBA1 gene mutations. The company also develops its preclinical and research pipeline comprising AL064, a tau siRNA for Alzheimer's disease and other tauopathies; ADP062-ABC, an alpha-synuclein siRNA for Parkinson's disease; and ADP065-ABC, an NLRP3 siRNA for neurodegenerative conditions. It has a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of progranulin-elevating monoclonal antibodies, including Latozinemab and Nivisnebart. The company was founded in 2013 and is headquartered in South San Francisco, California.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 241.69M |
| Enterprise Value | 21.90M | Income | -142.93M | Sales | 21.05M |
| Book/sh | 0.28 | Cash/sh | 2.32 | Dividend Yield | — |
| Payout | 0.00% | Employees | 103 | IPO | — |
| P/E | — | Forward P/E | -2.21 | PEG | — |
| P/S | 11.48 | P/B | 7.88 | P/C | — |
| EV/EBITDA | -0.15 | EV/Sales | 1.04 | Quick Ratio | 3.68 |
| Current Ratio | 3.83 | Debt/Eq | 118.22 | LT Debt/Eq | — |
| EPS (ttm) | -1.39 | EPS next Y | -0.99 | EPS Growth | — |
| Revenue Growth | -88.50% | Earnings | 2026-05-11 | ROA | -25.13% |
| ROE | -181.56% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -5.88% | Profit Margin | 0.00% | Shs Outstand | 110.36M |
| Shs Float | 86.40M | Short Float | 6.91% | Short Ratio | 6.51 |
| Short Interest | — | 52W High | 3.40 | 52W Low | 0.87 |
| Beta | 0.55 | Avg Volume | 1.07M | Volume | 938.98K |
| Target Price | $2.10 | Recom | Hold | Prev Close | $2.00 |
| Price | $2.19 | Change | 9.50% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$2.10
Mean price target
2. Current target
$2.19
Latest analyst target
3. DCF / Fair value
$-18.65
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.19
Low
$0.90
High
$5.00
Mean
$2.10
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-10-22 | down | TD Cowen | Buy → Hold | — |
| 2025-10-22 | down | Cantor Fitzgerald | Overweight → Neutral | — |
| 2025-10-22 | main | HC Wainwright & Co. | Buy → Buy | $5 |
| 2025-10-22 | down | William Blair | Outperform → Market Perform | — |
| 2025-10-22 | down | BTIG | Buy → Neutral | — |
| 2025-09-25 | reit | BTIG | Buy → Buy | $5 |
| 2025-07-28 | up | Mizuho | Neutral → Outperform | $4 |
| 2025-05-09 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-02-27 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-12-16 | down | Stifel | Buy → Hold | $4 |
| 2024-11-26 | down | Morgan Stanley | Equal-Weight → Underweight | $3 |
| 2024-11-26 | main | BTIG | Buy → Buy | $5 |
| 2024-11-26 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-11-07 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2024-09-17 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-09-09 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-07-29 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-06-20 | reit | Cantor Fitzgerald | — → Overweight | — |
| 2024-06-20 | reit | HC Wainwright & Co. | Buy → Buy | $35 |
| 2024-05-09 | main | HC Wainwright & Co. | Buy → Buy | $35 |
- $ALEC stock is down 15% today. Here's what we see in our data. - Quiver Quantitative Mon, 02 Mar 2026 19
- Alector Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewswire Wed, 25 Feb 2026 21
- Alector Stock Down After Latozinemab Failure, Eyes On Phase 2 Catalyst (ALEC) - Seeking Alpha ue, 16 Dec 2025 08
- Alector stock plummets after Phase 3 trial failure in FTD treatment - Investing.com ue, 21 Oct 2025 07
- Alector (NASDAQ: ALEC) cuts workforce 49%, ends INFRONT-3 extensions after endpoint not met - Stock Titan ue, 21 Oct 2025 07
- Alector (ALEC) Downgraded to Hold by TD Cowen | ALEC Stock News - GuruFocus Wed, 22 Oct 2025 07
- Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance Sun, 10 Aug 2025 07
- Volume Report: Is ALEC stock risky to hold now - 2025 Buyback Activity & Stepwise Swing Trade Plans - baoquankhu1.vn Fri, 06 Mar 2026 21
- Alec Holdings Rises in Dubai After $381 Million IPO - Bloomberg ue, 14 Oct 2025 07
- This Just In: Analysts Are Boosting Their Alector, Inc. (NASDAQ:ALEC) Outlook for This Year - simplywall.st Wed, 13 Aug 2025 07
- Alector Nears Crucial Phase 3 Results for First-Ever FTD Treatment as Cash Hits $307M - Stock Titan hu, 07 Aug 2025 07
- Alector Stock: Unlocking Middle Aged Dementia (NASDAQ:ALEC) - Seeking Alpha Mon, 06 Oct 2025 07
- Alector Stock Plummets 63% in a Month: Here's What You Need to Know - Yahoo Finance ue, 18 Nov 2025 08
- $ALEC stock is down 51% today. Here's what we see in our data. - Quiver Quantitative Wed, 22 Oct 2025 07
- Alector stock downgraded by William Blair after Phase III failure - Investing.com Wed, 22 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 3367 | 7012 | — | Sale at price 2.08 per share. | WONG-SARAD GRACE | Officer | — | 2026-03-03 00:00:00 | D |
| 1 | 81864 | 173822 | — | Sale at price 2.12 per share. | ROSENTHAL ARNON | Chief Executive Officer | — | 2026-03-02 00:00:00 | D |
| 2 | 29649 | 62954 | — | Sale at price 2.12 per share. | BERKLEY NEIL LINDSAY | Chief Financial Officer | — | 2026-03-02 00:00:00 | D |
| 3 | 8071 | 17138 | — | Sale at price 2.12 per share. | WONG-SARAD GRACE | Officer | — | 2026-03-02 00:00:00 | D |
| 4 | 4079 | 10198 | — | Sale at price 2.50 per share. | WONG-SARAD GRACE | Officer | — | 2026-02-26 00:00:00 | D |
| 5 | 4753 | 5751 | — | Sale at price 1.21 per share. | WONG-SARAD GRACE | Officer | — | 2025-12-05 00:00:00 | D |
| 6 | 104347 | 116827 | — | Sale at price 1.12 per share. | ROSENTHAL ARNON | Chief Executive Officer | — | 2025-12-03 00:00:00 | D |
| 7 | 41687 | 46673 | — | Sale at price 1.12 per share. | KENKARE-MITRA SARASWATI | President | — | 2025-12-03 00:00:00 | D |
| 8 | 37261 | 41717 | — | Sale at price 1.12 per share. | BERKLEY NEIL LINDSAY | Chief Financial Officer | — | 2025-12-03 00:00:00 | D |
| 9 | 8056 | 9019 | — | Sale at price 1.12 per share. | WONG-SARAD GRACE | Officer | — | 2025-12-03 00:00:00 | D |
Financials
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.21 |
| NormalizedEBITDA | -146.35M | -136.16M | -142.89M | -129.36M |
| NetIncomeFromContinuingOperationNetMinorityInterest | -142.93M | -119.05M | -130.39M | -133.31M |
| ReconciledDepreciation | 9.66M | 8.84M | 8.85M | 8.47M |
| EBITDA | -146.35M | -136.16M | -142.89M | -129.36M |
| EBIT | -156.01M | -145.00M | -151.74M | -137.83M |
| NormalizedIncome | -142.93M | -119.05M | -130.39M | -133.31M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -142.93M | -119.05M | -130.39M | -133.31M |
| TotalExpenses | 177.05M | 245.56M | 248.80M | 271.45M |
| TotalOperatingIncomeAsReported | -156.01M | -145.00M | -151.74M | -137.83M |
| DilutedAverageShares | 103.00M | 96.59M | 83.73M | 82.47M |
| BasicAverageShares | 103.00M | 96.59M | 83.73M | 82.47M |
| DilutedEPS | -1.39 | -1.23 | -1.56 | -1.62 |
| BasicEPS | -1.39 | -1.23 | -1.56 | -1.62 |
| DilutedNIAvailtoComStockholders | -142.93M | -119.05M | -130.39M | -133.31M |
| NetIncomeCommonStockholders | -142.93M | -119.05M | -130.39M | -133.31M |
| NetIncome | -142.93M | -119.05M | -130.39M | -133.31M |
| NetIncomeIncludingNoncontrollingInterests | -142.93M | -119.05M | -130.39M | -133.31M |
| NetIncomeContinuousOperations | -142.93M | -119.05M | -130.39M | -133.31M |
| TaxProvision | 168.00K | 128.00K | 5.21M | 3.25M |
| PretaxIncome | -142.76M | -118.92M | -125.18M | -130.06M |
| OtherIncomeExpense | 13.25M | 26.08M | 26.56M | 7.78M |
| OtherNonOperatingIncomeExpenses | 13.25M | 26.08M | 26.56M | 7.78M |
| OperatingIncome | -156.01M | -145.00M | -151.74M | -137.83M |
| OperatingExpense | 177.05M | 245.56M | 248.80M | 271.45M |
| ResearchAndDevelopment | 123.06M | 185.94M | 192.12M | 210.42M |
| SellingGeneralAndAdministration | 53.99M | 59.62M | 56.69M | 61.03M |
| GeneralAndAdministrativeExpense | 53.99M | 59.62M | 56.69M | 61.03M |
| OtherGandA | 53.99M | 59.62M | 56.69M | 61.03M |
| TotalRevenue | 21.05M | 100.56M | 97.06M | 133.62M |
| OperatingRevenue | 21.05M | 100.56M | 97.06M | 133.62M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 110.36M | 99.09M | 84.88M | 82.90M |
| ShareIssued | 110.36M | 99.09M | 84.88M | 82.90M |
| TotalDebt | 36.23M | 42.52M | 38.92M | 43.33M |
| TangibleBookValue | 30.65M | 126.80M | 134.16M | 214.44M |
| InvestedCapital | 40.34M | 136.19M | 134.16M | 214.44M |
| WorkingCapital | 196.95M | 299.76M | 387.86M | 632.63M |
| NetTangibleAssets | 30.65M | 126.80M | 134.16M | 214.44M |
| CapitalLeaseObligations | 26.54M | 33.13M | 38.92M | 43.33M |
| CommonStockEquity | 30.65M | 126.80M | 134.16M | 214.44M |
| TotalCapitalization | 39.97M | 136.19M | 134.16M | 214.44M |
| TotalEquityGrossMinorityInterest | 30.65M | 126.80M | 134.16M | 214.44M |
| StockholdersEquity | 30.65M | 126.80M | 134.16M | 214.44M |
| GainsLossesNotAffectingRetainedEarnings | 166.00K | 261.00K | 184.00K | -4.58M |
| OtherEquityAdjustments | 166.00K | 261.00K | 184.00K | -4.58M |
| RetainedEarnings | -972.06M | -829.13M | -710.08M | -579.69M |
| AdditionalPaidInCapital | 1.00B | 955.66M | 844.04M | 798.70M |
| CapitalStock | 11.00K | 9.00K | 8.00K | 8.00K |
| CommonStock | 11.00K | 9.00K | 8.00K | 8.00K |
| TotalLiabilitiesNetMinorityInterest | 262.59M | 341.50M | 487.67M | 573.21M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 193.09M | 216.44M | 309.72M | 479.40M |
| OtherNonCurrentLiabilities | 1.74M | 1.23M | 1.37M | 759.00K |
| NonCurrentDeferredLiabilities | 164.54M | 172.17M | 210.84M | 443.37M |
| NonCurrentDeferredRevenue | 164.54M | 172.17M | 210.84M | 443.37M |
| LongTermDebtAndCapitalLeaseObligation | 26.81M | 33.77M | 30.46M | 35.27M |
| LongTermCapitalLeaseObligation | 17.49M | 24.38M | 30.46M | 35.27M |
| LongTermDebt | 9.32M | 9.39M | ||
| LongTermProvisions | 9.28M | 67.05M | ||
| CurrentLiabilities | 69.50M | 125.06M | 177.95M | 93.81M |
| CurrentDeferredLiabilities | 6.68M | 23.66M | 82.97M | 48.23M |
| CurrentDeferredRevenue | 6.68M | 23.66M | 82.97M | 48.23M |
| CurrentDebtAndCapitalLeaseObligation | 9.42M | 8.75M | 8.46M | 8.06M |
| CurrentCapitalLeaseObligation | 9.06M | 8.75M | 8.46M | 8.06M |
| CurrentDebt | 366.00K | |||
| OtherCurrentBorrowings | 366.00K | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 12.94M | 18.21M | 15.30M | 12.76M |
| CurrentProvisions | 11.45M | 48.63M | 39.44M | |
| PayablesAndAccruedExpenses | 29.01M | 25.80M | 31.77M | 24.76M |
| CurrentAccruedExpenses | 10.03M | 17.67M | 20.30M | 20.57M |
| Payables | 18.98M | 8.13M | 11.48M | 4.19M |
| OtherPayable | 17.29M | 5.91M | 7.70M | |
| AccountsPayable | 1.69M | 2.21M | 3.77M | 4.19M |
| TotalAssets | 293.24M | 468.30M | 621.83M | 787.65M |
| TotalNonCurrentAssets | 26.79M | 43.49M | 56.02M | 61.21M |
| OtherNonCurrentAssets | 2.23M | 6.39M | 8.96M | 7.88M |
| NetPPE | 24.55M | 37.10M | 47.06M | 53.33M |
| AccumulatedDepreciation | -37.49M | -32.94M | -28.05M | -22.61M |
| GrossPPE | 62.05M | 70.04M | 75.11M | 75.94M |
| Leases | 24.94M | 26.36M | 26.62M | 26.23M |
| OtherProperties | 32.26M | 38.84M | 43.69M | 44.98M |
| MachineryFurnitureEquipment | 4.85M | 4.85M | 4.80M | 4.74M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 266.45M | 424.82M | 565.81M | 726.43M |
| OtherCurrentAssets | 10.43M | 11.42M | 16.95M | 11.00M |
| PrepaidAssets | 11.00M | 7.07M | ||
| Receivables | 0.00 | 2.59M | 7.39M | |
| DuefromRelatedPartiesCurrent | 0.00 | 2.59M | 7.39M | |
| CashCashEquivalentsAndShortTermInvestments | 256.02M | 413.40M | 548.86M | 712.85M |
| OtherShortTermInvestments | 190.22M | 380.38M | 474.31M | 558.53M |
| CashAndCashEquivalents | 65.80M | 33.02M | 74.56M | 154.32M |
| Line Item | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -184.07M | -231.16M | -186.54M | -24.45M |
| IssuanceOfDebt | 0.00 | 9.39M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 19.98M | 71.11M | 0.00 | 0.00 |
| CapitalExpenditure | -41.00K | -1.25M | -2.38M | -4.12M |
| InterestPaidSupplementalData | 855.00K | 0.00 | ||
| EndCashPosition | 67.65M | 34.87M | 76.10M | 155.79M |
| BeginningCashPosition | 34.87M | 76.10M | 155.79M | 330.62M |
| ChangesInCash | 32.78M | -41.23M | -79.69M | -174.83M |
| FinancingCashFlow | 20.21M | 81.54M | 2.55M | 4.51M |
| CashFlowFromContinuingFinancingActivities | 20.21M | 81.54M | 2.55M | 4.51M |
| ProceedsFromStockOptionExercised | 232.00K | 1.04M | 2.55M | 4.51M |
| NetCommonStockIssuance | 19.98M | 71.11M | 0.00 | 0.00 |
| CommonStockIssuance | 19.98M | 71.11M | 0.00 | 0.00 |
| NetIssuancePaymentsOfDebt | 0.00 | 9.39M | 0.00 | 0.00 |
| NetLongTermDebtIssuance | 0.00 | 9.39M | 0.00 | 0.00 |
| LongTermDebtIssuance | 0.00 | 9.39M | 0.00 | 0.00 |
| InvestingCashFlow | 196.60M | 107.13M | 101.92M | -159.01M |
| CashFlowFromContinuingInvestingActivities | 196.60M | 107.13M | 101.92M | -159.01M |
| NetInvestmentPurchaseAndSale | 196.64M | 108.39M | 104.30M | -154.90M |
| SaleOfInvestment | 468.52M | 576.13M | 656.03M | 402.00M |
| PurchaseOfInvestment | -271.88M | -467.74M | -551.73M | -556.90M |
| NetPPEPurchaseAndSale | -41.00K | -1.25M | -2.38M | -4.12M |
| PurchaseOfPPE | -41.00K | -1.25M | -2.38M | -4.12M |
| OperatingCashFlow | -184.03M | -229.91M | -184.16M | -20.33M |
| CashFlowFromContinuingOperatingActivities | -184.03M | -229.91M | -184.16M | -20.33M |
| ChangeInWorkingCapital | -74.06M | -146.99M | -90.15M | 59.53M |
| ChangeInOtherWorkingCapital | -21.05M | -100.56M | -66.78M | 66.38M |
| ChangeInOtherCurrentLiabilities | -56.11M | -51.94M | -28.87M | -3.67M |
| ChangeInOtherCurrentAssets | 4.16M | 2.87M | -1.01M | -835.00K |
| ChangeInPayablesAndAccruedExpense | -2.05M | -2.89M | 9.87M | -3.23M |
| ChangeInAccruedExpense | -12.90M | 340.00K | 2.55M | -2.65M |
| ChangeInPayable | 10.85M | -3.23M | 7.33M | -572.00K |
| ChangeInAccountPayable | -524.00K | -1.44M | -377.00K | -572.00K |
| ChangeInPrepaidAssets | 992.00K | 5.53M | -5.95M | -3.93M |
| ChangeInReceivables | 0.00 | 2.59M | 4.80M | -7.39M |
| OtherNonCashItems | 293.00K | |||
| StockBasedCompensation | 26.66M | 39.46M | 42.80M | 46.15M |
| AssetImpairmentCharge | 2.92M | 2.21M | 0.00 | 0.00 |
| AmortizationOfSecurities | -6.58M | -14.38M | -15.32M | -1.16M |
| DepreciationAmortizationDepletion | 9.66M | 8.84M | 8.85M | 8.47M |
| DepreciationAndAmortization | 9.66M | 8.84M | 8.85M | 8.47M |
| Depreciation | 9.66M | 8.84M | 8.85M | 8.47M |
| OperatingGainsLosses | 48.00K | |||
| GainLossOnSaleOfPPE | 0.00 | 48.00K | 0.00 | 0.00 |
| NetIncomeFromContinuingOperations | -142.93M | -119.05M | -130.39M | -133.31M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ALEC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|